Amgen loses appeal in patent suit against Sanofi/Regeneron’s Praluent. It’s a bummer for Bristol Myers Squibb and Merck, too

In a coda to a six-year legal fight on the PCSK9 terrain, the US Federal Court of Appeals has ruled that Amgen’s patent claims for PCSK9 antibodies as a class are invalid, handing a win to Sanofi and Regeneron.

The implications, though, may reverberate far beyond Amgen.